News and Information


02

2026-02

Weikang Bio visited Keyuan Pharmaceutical to jointly explore new pathways for pharmaceutical R&D!

On February 2, Professor Liu Pingsheng, founder and chairman of Weikang Shengsheng (Beijing) Biotechnology Co., Ltd. (hereinafter referred to as “Weikang Bio”), along with CEO Dr. Zhang Meng and other core team members, paid a visit to Keyuan Pharmaceutical (stock code: 301281.SZ) for an in-depth discussion. Also attending the meeting were Li Hongfu, Chairman of Keyuan Pharmaceutical; Gao Yuankun, Director; and Gao Chunpo, President.

2026-02-02

20

2026-01

Anchoring Metrics for Strategic Implementation | Keyuan Group Holds a Special Training Session on the “1+2 Strategic Plan” and the Achievement of 2026 Budget Targets

On January 20, Keyuan Group held a special meeting in Jinan to discuss its “1+2 Strategic Plan” and the budget targets for 2026. Attending the meeting were Li Hongfu, Chairman of Keyuan Group; Gao Chunpo, President of Keyuan Pharmaceutical; Wei Zhiguo, President of Linuo Pharmaceutical; as well as the group’s core management team and key business personnel. With “strategy-driven leadership and practical implementation as the priority” at its core, the meeting systematically laid out the group’s future development strategy and the roadmap for implementing its annual budget. The meeting also featured the full-time guidance and commentary of Professor Lan Tao, a doctoral graduate from the National University of Defense Technology and an expert in corporate strategic management.

2026-01-20

04

2026-01

Wang Bo and his delegation from Yaorongquan visited Kexuan Pharmaceutical to jointly explore industry trends and chart a new course for future development.

On January 14, Wang Bo, founder and chairman of Yaorongquan, and his delegation visited Keyuan Pharmaceutical and Linuo Pharmaceutical. The two sides conducted an in-depth inspection and held a symposium to discuss topics such as industry development trends, corporate product planning, and business strategy. Li Hongfu, chairman of Keyuan Pharmaceutical, and Gao Chunpo, president of the company, accompanied the delegation on the visit and jointly participated in this industry exchange.

2026-01-04

03

2026-01

Unite Hearts and Focus Efforts to Secure Victory in 2026 | Keyuan Pharmaceutical & Linuo Pharmaceutical Hold a 2025 Marketing Summary and 2026 First-Quarter Kickoff Meeting

The first-quarter bugle has sounded, and the drums of marketing are resounding throughout the land. On January 3, Keyuan Pharmaceutical (stock code: 301281.SZ) and Linuo Pharmaceutical successfully held their 2025 Marketing Summary Meeting and 2026 First-Quarter Kickoff Rally. Centered around the theme “Reviewing the Past, Seizing the First Quarter,” the meeting comprehensively summarized past achievements, set its sights on securing a strong start to the first quarter, and aimed to achieve new growth for the entire year.

2026-01-03

31

2025-12

Strategic Leadership, Comprehensive Advancement | New Year Greeting from Li Hongfu, Chairman of Keyuan Pharmaceutical!

Time refines craftsmanship, and the passage of years witnesses transformation. As the calendar for 2025 has already turned, this year has marked a pivotal milestone for Keyuan Pharmaceutical—a year of strategic upgrading, technological leaps, and industrial integration. Guided by our “Five-Year Vision,” we’ve harnessed the dual-engine of “chemical drugs + biologics” as our driving force and leveraged digital and intelligent transformation powered by “AI + computing power” as our wings. On the journey to safeguard human health, we’ve delivered an impressive, inspiring, and highly valuable annual report card.

2025-12-31

31

2025-12

Keyuan Pharmaceutical & Linuo Pharmaceutical: The 2025 Development Report

Time refines our original aspirations, and the passage of years engraves our path forward. As the year 2025 quietly comes to a close, Keyuan Pharmaceutical and Linuo Pharmaceutical, guided by the “Five Major Founding Principles” strategy, are steadily and confidently forging ahead on the journey of pharmaceutical and healthcare innovation—using industry as their foundation and craftsmanship as their ink—to compose a grand narrative of development that resonates with the times and walks hand in hand with life itself.

2025-12-31

31

2025-12

Read good books, welcome the New Year, and embark on a new journey.

A collection of箴言 gathers in Quancheng, and seven virtuous habits unlock the talents of tomorrow. On December 31—the very eve of the year’s end—Keyuan Pharmaceutical (stock code: 301281.SZ) Marketing Center concluded 2025 on a high note with a book-sharing session on “The 7 Habits of Highly Effective People.”

2025-12-31

27

2025-12

Working Together to Unite Our Strengths and Set Sail for a New Journey—Keyuan Pharmaceutical’s 7th Healthy Walking Event Comes to a Successful Conclusion

Together in unity, we join forces and set sail for a new journey! To enrich employees’ spiritual and cultural lives, enhance their physical fitness, strengthen team cohesion, and help the company achieve its annual business targets with flying colors, on December 27, Keyuan Pharmaceutical (stock code: 301281.SZ) kicked off its 7th “Together in Unity, Gathering Strength for the Future” health walking event in a warm and uplifting atmosphere. The company’s management team, along with nearly 200 employees from various functional departments and frontline production teams, enthusiastically embarked on this hiking journey brimming with solidarity and determination.

2025-12-27

19

2025-11

Public Information on the Environmental Impact Assessment for Shandong Keyuan Pharmaceutical Co., Ltd.'s High-Efficiency, Continuous-Flow Digital Intelligent Factory Project for Isosorbide Mononitrate

According to the "Measures for Public Participation in Environmental Impact Assessment" (Ministry of Ecology and Environment Order No. 4), "Article 20: Before submitting the environmental impact report for approval to the ecological and environmental authorities, the project proponent shall publicly disclose the full text of the draft environmental impact report and the public participation statement via an online platform."

2025-11-19

18

2025-11

Publicly Available Information: Environmental Impact Assessment Report (Draft for Comments) on the Intelligent Pilot-Scale Platform Project for Specialized, Fine, and Novel Active Pharmaceutical Ingredients at Shandong Keyuan Pharmaceutical Co., Ltd.

Shandong Keyuan Pharmaceutical Co., Ltd. has completed the Environmental Impact Assessment Report (Draft for Comments) of its Intelligent Pilot-Scale Platform Project for Specialty and Innovative Active Pharmaceutical Ingredients.

2025-11-18

< 1234...12 >